July 20, 2020


Our tax dollars are hard at work, developing new treatmentsto keep all of us healthy.

On July 14, 2020, the New England Journal of Medicinepublished successful results using Moderna’s new treatment to prevent severeCOVID-19 infections. https://www.nejm.org/doi/full/10.1056/NEJMoa2022483

Chief investigator Dr. Lisa Jackson at the Kaiser PermanenteWashington Health Research Institute in Seattle, Washington and hercollaborators stated: “The mRNA1273 vaccine induced anti–SARS-CoV-2 immuneresponses in all participants, and no trial-limiting safety concerns wereidentified. These findings support further development of this vaccine.”

Moderna has been working closely with and funded in part byAmerica’s talented infectious disease experts at the National Institute ofAllergy and Infectious Disease (NIAID) to create a safe and effectiveant-COVID-19 treatment, and thus far it appears to be a success. (NIAID:https://www.niaid.nih.gov/ Moderna: https://www.modernatx.com/

Quoting the article: “We conducted a phase 1,dose-escalation, open-label trial including 45 healthy adults, 18 to 55 yearsof age, who received two vaccinations, 28 days apart, with mRNA-1273 in a doseof 25 μg, 100 μg, or 250 μg. There were 15 participants in each dose group.”Fatigue, chills and localized pain were common, as expected.

As seen below, their results indicate two 100 microgram (100ug) injections of messenger RNA (mRNA) that codes for production of the virus’spike protein will be safe and effective in preventing severe Coronavirus-2infections. Additional studies are underway in three thousand volunteers toconfirm these initial findings, the results of which will be available laterthis year.

Help is on the way…

May 19, 2020

New COVID-19 Vaccine

It was widely reported on May 17, 2020, that Moderna corporation’s new mRNA based vaccine induced anti-viral antibodies to the SARS-CoV-2 coronavirus in 8 volunteers, which may lead to the prevention of life-threatening coronavirus-2 infections. https://www.cnn.com/2020/05/18/health/coronavirus-vaccine-moderna-early-results/index.html

Moderna is working with the National Institute of Health (NIH) in the most important vaccine research in the past century. If future studies go well, the company's vaccine could be available to the public as early as January, Dr. Tal Zaks, Moderna's chief medical officer, told CNN. "This is absolutely good news and news that we think many have been waiting for for quite some time," Zaks said. https://www.cnn.com/2020/05/18/health/coronavirus-vaccine-moderna-early-results/index.html

The CoV-2 virus infects human cells in human respiratory and gastrointestinal systems using ACE2 receptors - as depicted below. This new vaccine may be able to protect humans by neutralizing the virus before it infects its victim.

Moderna and the NIH will continue testing this new vaccine in many more volunteers prior to allowing everyone to receive it.So, there is Hope we will overcome the COVID-19 Pandemic by next year.

schedule now
Contact Us800-ALL-WELL®

sign up for our

kagen allergy ® newsletter

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
©2020 The Kagen Allergy Clinic SC. All Rights Reserved.
$('.w-nav-menu').on('click', 'a', function() { if ($('.w--open').length === 1){ // detect whether menu is open in mobile view $('.w-nav-button').triggerHandler('tap'); } });